-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
1/25
Biosafety AssessmentBiosafety Assessment
Of GeneticallyOf GeneticallyModified Crops.Modified Crops.
Charu Sharma (2010)Richa Gupta (2024)Divya Tarkar (2068)
Presented by:-
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
2/25
a area areBIOHAZARDS?BIOHAZARDS?
A biological hazard or biohazard is anorganism, or substance derived from anorganism, that poses a threat to (primarily)human health.This can include medical waste or samples of a
microorganism , virus or toxin (from a biologicalsource) that can impact human health. It can
also include substances harmful to animals.
http://en.wikipedia.org/wiki/Microorganismhttp://en.wikipedia.org/wiki/Virushttp://en.wikipedia.org/wiki/Toxinhttp://en.wikipedia.org/wiki/Toxinhttp://en.wikipedia.org/wiki/Virushttp://en.wikipedia.org/wiki/Microorganism -
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
3/25
and Potentiallyand PotentiallyInfectious MaterialsInfectious Materials
Human, animal and plant pathogens;All human blood, blood products, tissues andcertain body fluids;Cultured cells (all human or certain animal) andpotentially infectious agents these cells maycontain;Allergens;
Toxins (bacterial, fungal, plant, etc.);Certain recombinant products;Clinical specimens;Infected animals and animal tissues;Recombinant DNA (rDNA);
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
4/25
Risk AssessmentRisk Assessment
"Risk" implies the probability that harm, injury ordisease will occur.
In the context of the microbiological and biomedicallaboratories, the assessment of risk focuses primarilyon the prevention of laboratory-associated infections.
It helps to assign the biosafety levels (facilities,equipment, and practices) that reduce the worker'sand the environment's risk of exposure to an agent toan absolute minimum.
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
5/25
Factors of Interest in aFactors of Interest in aRisk AssessmentRisk Assessment
1. The pathogenicity of the infectious or suspectedinfectious agent, including disease incidence and severity(i.e., mild morbidity versus high mortality, acute versuschronic disease). The more severe the potentiallyacquired disease, the higher the risk.
2. The route of transmission (e.g., parenteral, airborne,ingestion) of newly isolated agents may not bedefinitively established. Agents that can be transmittedby the aerosol route have caused most laboratoryinfections. I
3. Agent stability is a consideration that involves not onlyaerosol infectivity (e.g., from spore-forming bacteria),but also the agent's ability to survive over time in theenvironment.
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
6/25
Factors of Interest in aFactors of Interest in aRisk Risk AssessmentAssessment
4. The infectious dose :- It can vary from one to hundreds of thousands of units.
5. The concentration (number of infectious organisms per unitvolume) :- It will include consideration of the milieucontaining the organism (e.g., solid tissue, viscous blood orsputum, liquid medium) and the laboratory activity planned(e.g., agent amplification, sonication, centrifugation).
6. The origin of the potentially infectious material :- "Origin"
may refer to geographic location (e.g., domestic, foreign);host (e.g., infected or uninfected human, animal); or natureof source (e.g., potential zoonotic, associated with a diseaseoutbreak).
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
7/25
Risk GroupsRisk GroupsRisk Group 1 Agents that are not associated with disease in
healthy adult humans.
Risk Group 2 Agents that are associated with human diseasewhich is rarely serious and for which preventiveor therapeutic interventions are often available.
Risk Group 3 Agents that are associated with serious or lethalhuman disease for which preventive ortherapeutic interventions may be available (highindividual risk but low community risk).
Risk Group 4 Agents that are likely to cause serious or lethalhuman disease for which preventive ortherapeutic interventions are not usuallyavailable (high individual risk but high community
risk).
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
8/25
Biosafetyregulation and
safetyrequirements in GM
crops and food
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
9/25
safety requirements in GMsafety requirements in GMcrops and foodcrops and food
Crops can be divided broadly into six categories inaccordance with their invasive potential:
Crops that have no compatible relatives, carry few
weediness traits (less than 40 percent), and do notpersist in natural environments.
Crops that have no compatible relatives, carryintermediate numbers of weediness traits, rarelyescape, and do not persist in natural environments.
Crops that have no compatible wild relatives, carrymany weediness traits, and can escape and persist innatural environments.
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
10/25
safety requirements in GMsafety requirements in GMcrops and foodcrops and food
Crops that have compatible relatives, carry fewweediness traits, and can escape but do not persist innatural environments and dot not spread aggressively.
Crops that have compatible relatives, carry intermediatenumbers of weediness traits, and can escape but do notpersist in natural environments; their compatiblerelatives also carry few weediness traits and do notspread aggressively.
Crops that have compatible wild relatives, carry manyweediness traits, and can escape and persist in naturalenvironments; their compatible relatives also carry manyweediness traits and spread aggressively .
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
11/25
Genetically ModifiedGenetically ModifiedCropsCrops
Persistence of the transgene or of thetransgene productsGene flowResistance/tolerance of targetorganisms
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
12/25
Genetically ModifiedGenetically ModifiedCropsCrops
Loss of biodiversityChanges in the soil ecology
Changes in nutritional level
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
13/25
Containment facility forGM plant
Containment is a term used forphysical barriers to restrict the spreadwithin a structure or enclosed space.
The basic biosafety requirement in thedevelopment of a GMO is to limit spreadof the GMO and its genetic material.A relatively high level of control can beachieved in the laboratory facilitiesincluding pilot scale fermentation andsmall-scale field trials in greenhouses.
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
14/25
La oratorycontainment
Physical containment of GMOs is maintained bygood laboratory practices. Care should betaken that the laboratory facilities are in line
with the risk category of the target organism. Itis necessary to ensure that the organismsproduced under lab conditions are carefullycollected for subsequent use or disposal.
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
15/25
reen ousecontainment
For higher level of containment, facilities haveto meet specifications such as controlled andfiltered airflow, systems to control and disinfect
water leaving the facility, autoclaves for on-sitesterilization of plant material and equipment,disinfecting the facility after experiments, strictlimits on who is allowed to enter including thatof staff and trainee.
k
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
16/25
Risk managementstrategies
Confinement- For preventing and minimizing theunintentional spread of GMO or a genetic material,measures should be taken to confine them within a
site/zone having designated borders/limits. This canbe used by both physical and biological means.
-Physical-Biological
Monitoring
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
17/25
Physical ConfinementPhysical means to confine GMOs particularly in case of plants and animals consist of geographical or spatialisolation by the use of structures such as fences,screens, mesh etc.
The access to the site should be controlled. In case of plants, appropriate isolation distance should be workedout to control the fertilization of sexually compatiblespecies growing in the vicinity by transgenic pollen.
It is essential to collect information about the presenceand distribution of cross-fertile wild or weedy relativesof cultivated species near the proposed site.
l l
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
18/25
BiologicalConfinement
GM plants may be grown in an area where sexuallycompatible wild or weedy species are not found.
All plants of sexually compatible wild or weedy speciesfound within the known effective pollinating distance of theGM crop may be removed.
Flowers may be covered with bags to screen out insectpollinators or prevent wind pollination.
Tubers, rhizomes, storage roots, and all tissues capable of developing into mature plants under natural conditionsmay be recovered.
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
19/25
Strategies in Monitoring
Accept and involve the public as a legitimate partner and treatadversaries with respect
Coordinate, collaborate and provide information through crediblesources
Be honest, frank and open, dont keep secrets and acknowledgemistakes made
Listen to and acknowledge peoples concerns
Be proactive and speak clearly with a balanced and realisticinformation strategy
Meet the needs of the media and identify and train communicators
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
20/25
Biosafety
Regulatory bodiesin India for GMplants
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
21/25
Biosafety rules in India forGM plants
Presently, there are three regulatoryauthorities to regulate recombinant DNArelated activities including research, productdevelopment and commercialization activity.
These are(a) Institutional Biosafety Committee (IBSC);(b) Review Committee on GeneticManipulation (RCGM) and
(c) Genetic Engineering Approval Committee(GEAC).
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
22/25
Institutional BiosafetyCommittee (IBSC)
To note, examine and approve proposals involvingr-DNA work; to ensure adherence of r-DNA SafetyGuidelines- 1990 of Government; inspection of containment facilities at R&D and production unitsand to inform the RCGM about the facilities;
To recommend for import/ exchange of GMOs/LMOs/Transgenic seeds, vectors, geneconstructs, plasmids, etc., for research purposes
To prepare emergency plan according toguidelines;
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
23/25
Genetic Manipulation(RCGM):
To note and to approve r-DNA work. To ensure adherence of r-DNA safetyguidelines of government.
To prepare emergency plan according toguidelines.
To act as nodal point for interaction withstatutory bodies.
To ensure experimentation at designatedlocation, taking into account approvedprotocols.
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
24/25
Approval Committee(GEAC):
To permit the use of GMOs and products thereof forcommercial applications.
To adopt producers for restriction or prohibition,production, sale, import & use of GMOs both forresearch and applications under EPA.
To authorize large-scale production and release of GMOs and products thereof into the environment.
To authorize agencies or persons to have powers to
take punitive actions under the EnvironmentProtection Act.
-
8/14/2019 Biosafety Assessment of ant Organism and Vaccines Final
25/25